Study S000569

Prednisolone-induced Impairment of Glucose Metabolism and Beta-cell Dysfunction and the Protective Effects of Exenatide: a Single-center, Randomized, Double-blind, Placebo-controlled Crossover Study in Healthy Volunteers

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT00744224
Acronym: PREDEX
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: DOUBLE
Status: COMPLETED
Enrollment: 8
Start: 2009-02
Primary completion: 2010-01
Lead sponsor: Amsterdam UMC, location VUmc
Conditions: Glucocorticoid-induced Glucometabolic Abnormalities; Glucocorticoid-induced Beta-cell Dysfunction
Interventions: DRUG:Placebo; DRUG:Prednisolone; DRUG:Prednisolone and Exenatide
Results posted: FALSE

Registered primary outcomes

To assess whether a single day infusion of the GLP-1 RA exenatide, as compared to placebo, reverses GC-induced impairment of glucose metabolism in healthy males, quantified as glucose tolerance (AUCgluc) during a standardized mixed-meal test [Single-day treatment]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0014060	Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. van Raalte DH, Diabetes care	2011	Randomized trial	PMID 21216851 DOI	cites ClinicalTrials.gov:NCT00744224; registry reference DERIVED:21216851